drugset / Trial / NCT03593278
A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to investigate how quickly and to what extent ACT-246475 is absorbed, distributed, metabolized (broken down) and eliminated from the body. ACT-246475 will be labeled with 14-Carbon (14C) and, in this way can be traced in blood, urine, and feces. This study will also investigate how safe is ACT-246475 and how well it is tolerated when administered to healthy male volunteers.
Timeline
- Start
- 2018-07-27
- Primary completion
- 2018-08-05
- Completion
- 2018-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selatogrel | Small molecule | 16 mg | Subcutaneous |
Indications
No indication recorded.